These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17901561)

  • 1. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment.
    Berthiaume JM; Wallace KB
    Cardiovasc Toxicol; 2007; 7(3):178-91. PubMed ID: 17901561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
    Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
    Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.
    Zordoky BN; Anwar-Mohamed A; Aboutabl ME; El-Kadi AO
    Toxicol Appl Pharmacol; 2010 Jan; 242(1):38-46. PubMed ID: 19796650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
    Sun X; Zhou Z; Kang YJ
    Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats.
    Alsaad AM; Zordoky BN; El-Sherbeni AA; El-Kadi AO
    Drug Metab Dispos; 2012 Nov; 40(11):2126-35. PubMed ID: 22867862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
    Saad SY; Najjar TA; Alashari M
    J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio.
    Childs AC; Phaneuf SL; Dirks AJ; Phillips T; Leeuwenburgh C
    Cancer Res; 2002 Aug; 62(16):4592-8. PubMed ID: 12183413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets.
    Sardão VA; Oliveira PJ; Holy J; Oliveira CR; Wallace KB
    Cell Biol Toxicol; 2009 Jun; 25(3):227-43. PubMed ID: 18386138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats--relevance for mitochondrial dysfunction.
    Oliveira PJ; Wallace KB
    Toxicology; 2006 Mar; 220(2-3):160-8. PubMed ID: 16427179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats.
    Zhou S; Heller LJ; Wallace KB
    Toxicol Appl Pharmacol; 2001 Aug; 175(1):60-7. PubMed ID: 11509027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction.
    Hydock DS; Lien CY; Schneider CM; Hayward R
    Med Sci Sports Exerc; 2008 May; 40(5):808-17. PubMed ID: 18408619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction.
    Berthiaume JM; Oliveira PJ; Fariss MW; Wallace KB
    Cardiovasc Toxicol; 2005; 5(3):257-67. PubMed ID: 16244371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
    Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
    Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain.
    Hydock DS; Wonders KY; Schneider CM; Hayward R
    Anticancer Res; 2009 Nov; 29(11):4401-7. PubMed ID: 20032385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress and myocardial gene alterations associated with Doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation.
    Richard C; Ghibu S; Delemasure-Chalumeau S; Guilland JC; Des Rosiers C; Zeller M; Cottin Y; Rochette L; Vergely C
    J Pharmacol Exp Ther; 2011 Dec; 339(3):807-14. PubMed ID: 21934029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
    Working PK; Newman MS; Sullivan T; Yarrington J
    J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent effects of doxorubicin on cardiac gene expression.
    Boucek RJ; Miracle A; Anderson M; Engelman R; Atkinson J; Dodd DA
    J Mol Cell Cardiol; 1999 Aug; 31(8):1435-46. PubMed ID: 10423342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to protect doxorubicin-induced cardiomyopathy in male albino rats?
    Shaker O; Sourour DA
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute exercise protects against doxorubicin cardiotoxicity.
    Wonders KY; Hydock DS; Schneider CM; Hayward R
    Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.